awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26746901-141B4C3D-F7EE-4840-861C-B07B1A61F479
Q26746901-141B4C3D-F7EE-4840-861C-B07B1A61F479
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26746901-141B4C3D-F7EE-4840-861C-B07B1A61F479
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
P2860
Q26746901-141B4C3D-F7EE-4840-861C-B07B1A61F479
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26746901-141B4C3D-F7EE-4840-861C-B07B1A61F479
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
aa841df17ee989ceb28701a422c26e4dc428672b
P2860
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.